Answers are grounded in this paper and cite their sources.
The transcription factor TBXT plays a pivotal role in vertebrate embryogenesis and has emerged as a key regulator in some cancers. During embryonic development, TBXT governs notochord differentiation and posterior body elongation, with its expression tightly controlled by signaling pathways including Nodal/Activin, bone morphogenetic protein (BMP), fibroblast growth factor (FGF), WNT, and retinoic acid (RA). These pathways act through conserved and species-specific cis-regulatory elements (CREs) that integrate activating and repressive inputs to ensure precise spatiotemporal expression. Beyond development, TBXT is aberrantly expressed in multiple cancers and functions in a context-dependent manner, acting as a driver in chordoma and promoting metastasis and poor prognosis in epithelial cancers such as triple-negative breast and non-small cell lung cancer, while exerting a protective role in glioma. Its dysregulation is influenced by signaling pathways including FGF, phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), transforming growth factor β (TGF-β), WNT, and hypoxia, and by epigenetic mechanisms. Notably, a super-enhancer downstream of TBXT drives its expression in chordoma, but the specific CREs that drive expression in other cancers remain uncharacterized. Elucidating how signaling pathways and CREs interact to regulate TBXT expression may offer avenues for targeted therapeutic interventions in cancers dependent on TBXT.
No takes yet. Share an insight, caveat, or question.
Kongprajug et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: